Evidence map›Paper›PMID 38956517›Full record

ArticleBMC public health2024

SARS-CoV-2 seroprevalence among Beninese pregnant women in the third year of the pandemic.

Antía Figueroa-Romero, Aurore Atchadé, Anges Yadouleton, Marc Fiogbe, Emmanuel Bonnet, Emmanuel Yovo, Manfred Accrombessi, Sandrine Hounsa, Thierry Paper, Raphael Dupont and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06170320 (STREngthening Epidemiological Surveillance in Benin and Burkina Faso for an Effective Response to COVID-19), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06170320 completednot on this map

STREngthening Epidemiological Surveillance in Benin and Burkina Faso for an Effective Response to COVID-19

TypeobservationalSponsorInstitut de Recherche pour le DeveloppementRan2021 to 2022Enrolled7,000ConditionsCOVID-19, SARS CoV 2 Infection, COVID-19 Pandemic
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Antía Figueroa-Romero *Barcelona Institute for Global Health (ISGlobal), Hospital Clínic- Universitat de Barcelona, Barcelona, Spain. antia.figueroa@isglobal.org.
Aurore Atchadé *Institut de Recherche Clinique du Bénin, Abomey-Calavi, Benin.
Anges YadouletonLaboratoire des fièvres hémorragiques virales du Bénin, Ministère de la Santé du Bénin, Cotonou, 01BP918, Bénin.
Marc FiogbeInstitut de Recherche Clinique du Bénin, Abomey-Calavi, Benin.
Emmanuel BonnetInstitut de recherche pour le développement PRODIG UMR 215, CNRS Université Paris 1 Panthéon- Sorbonne, AgroParisTech 5, cours des Humanités, Aubervilliers, Île-de-France, F-93 322, France.
Emmanuel YovoInstitut de Recherche Clinique du Bénin, Abomey-Calavi, Benin.
Manfred AccrombessiInstitut de Recherche Clinique du Bénin, Abomey-Calavi, Benin.
Sandrine HounsaInstitut de Recherche Clinique du Bénin, Abomey-Calavi, Benin.
Thierry PaperBiosynex S.A, 22 boulevard Sebastien Brant, Illkirch Graffenstaden, Strasbourg, F-67400, France.
Raphael DupontBiosynex S.A, 22 boulevard Sebastien Brant, Illkirch Graffenstaden, Strasbourg, F-67400, France.
Jean GaudartAix Marseille Univ, IRD, INSERM, SESSTIM, ISSPAM, AP-HM, Hop La Timone, BioSTIC, Biostatistic and ICT, Marseille, France.
Jean-Yves Le HesranInstitut de Recherche pour le Développement, MERIT UMR216, Université Paris-Cité, Faculté de pharmacie, laboratoire de parasitologie, Paris, France.
Achille MassougbodjiInstitut de Recherche Clinique du Bénin, Abomey-Calavi, Benin.
Gilles CottrellInstitut de Recherche pour le Développement, MERIT UMR216, Université Paris-Cité, Faculté de pharmacie, laboratoire de parasitologie, Paris, France.
Raquel GonzálezBarcelona Institute for Global Health (ISGlobal), Hospital Clínic- Universitat de Barcelona, Barcelona, Spain.

Funding

European and Developing Countries Clinical Trials Partnership RIA2020EF-2923-STREESCOMinisterio de Ciencia y Tecnología CEX2018-000806-S
6 · The paper itself

Abstract

backgroundPregnant women are a vulnerable population to COVID-19 given an increased susceptibility to severe SARS-CoV-2 infection and pregnancy complications. However, few SARS-CoV-2 serological surveys have been performed among this population to assess the extent of the infection in sub-Saharan countries. The objectives of this study were to determine SARS-CoV-2 seroprevalence among Beninese pregnant women, to identify spatial seropositivity clusters and to analyse factors associated with the infection.

methodsA cross-sectional study including women in their third trimester of pregnancy attending the antenatal care (ANC) clinics at Allada (south Benin) and Natitingou (north Benin) was conducted. Rapid diagnostic tests (RDT) for detection of IgG/IgM against the SARS-CoV-2 spike protein were performed using capillary blood. Seroprevalence of SARS-CoV-2 antibodies and associations between SARS-CoV-2 serostatus and maternal characteristics were analyzed by multivariate logistic regression. Spatial analyses were performed using the spatial scan statistics to identify spatial clusters of SARS-CoV-2 infection.

resultsA total of 861 pregnant women were enrolled between May 4 and June 29, 2022. 58/861 (6.7%) participants reported having received COVID-19 vaccine. None of the participants had been diagnosed with COVID-19 during their pregnancy. SARS-CoV-2 antibodies were detected in 607/802 (75.7%; 95% CI 72.56%-78.62%) of unvaccinated participants. Several urban and rural spatial clusters of SARS-CoV-2 cases were identified in Allada and one urban spatial cluster was identified in Natitingou. Unvaccinated participants from Allada with at least one previous morbidity were at a three-times higher risk of presenting SARS-CoV-2 antibodies (OR = 2.89; 95%CI 1.19%-7.00%).

conclusionThree out of four pregnant women had SARS-CoV-2 antibodies, suggesting a high virus circulation among pregnant women in Benin, while COVID-19 vaccination coverage was low. Pregnant women with comorbidities may be at increased risk of SARS-CoV-2 infection. This population should be prioritized for COVID-19 diagnosis and vaccination in order to prevent its deleterious effects.

trial registrationNCT06170320 (retrospectively registered on December 21, 2023).

Indexed as

COVID-19Pregnancy Complications, InfectiousSARS-CoV-2AdultAntibodies, ViralBeninCross-Sectional StudiesFemaleHumansPregnancyPregnancy Trimester, ThirdSeroepidemiologic StudiesYoung AdultAntibodies, ViralPregnancySARS-CoV-2Sub-saharan Africa

Identifiers

PMID38956517
PMCPMC11221113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.